Surv BioPharma Inc.
PrivateLast Round
Series B
Extension
Dec 23, 2025
Total Funding Raised
$38.69M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Surv BioPharma Inc. is a biopharmaceutical company that develops oncolytic viruses and in vivo gene therapies for cancers and other diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Surv BioPharma Inc. Comparables
Compare Surv BioPharma Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lokon Pharma | 79% | |
| Theriva Biologics | 77% | |
| SillaJen Inc | 75% |
Surv BioPharma Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 23, 2025 | ||||
| Grant | Dec 4, 2025 | ||||
| Series B | Nov 11, 2025 | ||||
| Seed | Dec 28, 2022 |
Surv BioPharma Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Agency for Medical Research and Development | Grant |
| Tokai Tokyo Investment Co., Ltd. | Series B |
| Keio Innovation Initiative | Series B |
| Oita Venture Capital Co., Ltd. | Series B Extension |
| 日本ベンチャーキャピタル株式会社 | Series B |
| Kagoshima Development Co., Ltd. | Seed, Series B |
| 株式会社FFGベンチャービジネスパートナーズ | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 23, 2025
$4.3M round with participation from TOHO HOLDINGS.
- Dec 4, 2025
$17.3M grant from Japan Agency for Medical Research and Development.
Surv BioPharma Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Surv BioPharma Inc.'s valuation, stock price, and market status.
Is Surv BioPharma Inc. a public or private company?
Surv BioPharma Inc. is a private company.
What is the current stock price of Surv BioPharma Inc.?
Surv BioPharma Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Surv BioPharma Inc. worth (valuation)?
Valuation information for Surv BioPharma Inc. is not publicly available.
Can I buy Surv BioPharma Inc. stock?
Surv BioPharma Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Surv BioPharma Inc.'s last funding round?
Surv BioPharma Inc.'s most recent funding round was Series B Extension on December 23, 2025.
Who are the main investors in Surv BioPharma Inc.?
Key investors in Surv BioPharma Inc. include Keio Innovation Initiative.
Will Surv BioPharma Inc. IPO soon?
No public IPO plans have been announced for Surv BioPharma Inc..
How can I track Surv BioPharma Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Surv BioPharma Inc.'s secondary market activity and sign up for updates.